Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTG-001 Bioavailability and PK Study
NCT07341152Phase 1Completed
- Sponsor
- Latigo Biotherapeutics
- Start
- Oct 2025
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LTG-001 in pain, sponsored by Latigo Biotherapeutics. Primary endpoints: Relative Bioavailability of Crystalline Formulations vs SDD, Pharmacokinetics of LTG-001 and 2 more. Started Oct 2025; status: completed.
02
Drugs
LTG-001
03
Conditions
pain
Beyond the preview
Go deeper on NCT07341152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07341152.